Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

2,357 recalls · Class II, newest first

Class II · Moderate risk

Moxifloxacin Preservative Free Syr

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0040-2023
Class II · Moderate risk

MITOMYCIN INJECTION 0.375 mg/mL SYR

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0039-2023
Class II · Moderate risk

METHYLCOBALAMIN PF 1 ML Injection Solution 5

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0038-2023
Class II · Moderate risk

LAURETH-9 INJ 2% Solution

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0034-2023
Class II · Moderate risk

GLYCERIN OPHTHALMIC DROPS 98.5% Solution

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0033-2023
Class II · Moderate risk

CEFTAZIDIME INTRAVITREAL 2.25MG/0.1ML Solution

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0030-2023
Class II · Moderate risk

Brilliant Blue G

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0029-2023
Class II · Moderate risk

Autologus Tears Serum Soln Full Strength

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0028-2023
Class II · Moderate risk

ACETYLCYSTEINE OPTH 5% Solution

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0027-2023
Class II · Moderate risk

ACETYLCYSTEINE OPTH 10% Solution

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0026-2023
Class II · Moderate risk

SIREtizer Hand Sanitizer

CGMP Deviations and Superpotent Drug: Levels of acetal and acetaldehyde above allowable limits. Additionally, lot 001 was superpotent.

Ongoing Wrong potency / content Southwest Iowa Renewable Energy LLC D-0166-2023
Class II · Moderate risk

Rifampin Capsules

Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).

Ongoing Nitrosamine impurity Akorn, Inc. NDC 61748-018-30 D-1548-2022
Class II · Moderate risk

Rifampin Capsules

Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).

Ongoing Nitrosamine impurity Akorn, Inc. NDC 61748-015-30 D-1547-2022

Recalls by year